Overview

Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension

Status:
Completed

Trial end date:
2005-01-01

Target enrollment:

Participant gender:

Summary

Primary: - To evaluate the impact of irbesartan on endothelial function in hypertensive patients with metabolic syndrome. Secondary: - To evaluate the oxidative stress status in patients with hypertension with metabolic syndrome. - To correlate the oxidative stress status with endothelial function in these patients. - To evaluate the effect of irbesartan on the oxidative stress stage in patients with metabolic syndrome and to correlate it with the effect on endothelial function . - To correlate the change in endothelial function and oxidative stress stage with the change of arterial pressure levels.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Angiotensin Receptor Antagonists
Atenolol
Irbesartan